Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

Wael Saber, Corey S. Cutler, Ryotaro Nakamura, Mei Jie Zhang, Ehab Atallah, J. Douglas Rizzo, Richard T. Maziarz, Jorge Cortes, Matt E. Kalaycio, Mary M. Horowitz

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

Allogeneic hematopoietic cell transplantation (HCT) from human leukocyte antigen (HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces similar survival for patients with acute myelogenous leukemia.Whether these results can be extended to patientswithmyelodysplastic syndromes (MDS) is unknown. Therefore, analysis of post-HCT outcomes for MDS was performed. Outcomes of 701 adult MDS patients who underwent HCT between 2002 and 2006 were analyzed (MRD [n 5 176], 8 of 8 HLA-A, -B, -C, -DRB1 allele matchedMUD [n 5 413], 7 of 8 MUD [ n 5 112]). Median agewas 53 years (range, 22-78 years). In multivariate analyses, MRD HCT recipients had similar disease free survival (DFS) and survival rates compared with 8 of 8 MUD HCT recipients (relative risk [RR] 1.13 [95% confidence interval (CI) 0.91-1.42] and 1.24 [95% CI 0.98-1.56], respectively), and both MRD and 8 of 8MUD had superior DFS(RR1.47 [95%CI 1.10-1.96] and 1.29 [95%CI 1.00-1.66], respectively) and survival (RR 1.62 [95% CI 1.21-2.17] and 1.30 [95% CI 1.01-1.68], respectively) compared with 7 of 8 MUDHCT recipients. In patients with MDS, MRD remains the best stem cell source followed by 8 of 8 MUD. Transplantation from 7 of 8 MUD is associated with significantly poorer outcomes.

Original languageEnglish (US)
Pages (from-to)1974-1982
Number of pages9
JournalBlood
Volume122
Issue number11
DOIs
StatePublished - Sep 12 2013
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)'. Together they form a unique fingerprint.

Cite this